Search company, investor...

Drais Pharmaceuticals

draispharma.com

Founded Year

2007

Stage

Series A | Alive

Total Raised

$15M

Last Raised

$15M | 15 yrs ago

About Drais Pharmaceuticals

Drais Pharmaceuticals, Inc. is dedicated to the development of therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.

Headquarters Location

520 US Highway 22 Suite 201

Bridgewater, New Jersey, 08807,

United States

908-895-1200

Missing: Drais Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Drais Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Drais Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Drais Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Drais Pharmaceuticals Patents

Drais Pharmaceuticals has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/30/2007

4/2/2013

Prodrugs, G protein coupled receptors, Clusters of differentiation, Transcription factors, Antineoplastic drugs

Grant

Application Date

3/30/2007

Grant Date

4/2/2013

Title

Related Topics

Prodrugs, G protein coupled receptors, Clusters of differentiation, Transcription factors, Antineoplastic drugs

Status

Grant

Latest Drais Pharmaceuticals News

Drais Pharmaceuticals Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Nov 28, 2016

Drais Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 14:46 EST 28 Nov 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Drais Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Drais Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Drais Pharmaceuticals, Inc. since January 2007. Key Findings Provides intelligence on Drais Pharmaceuticals, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Drais Pharmaceuticals, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Drais Pharmaceuticals, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Drais Pharmaceuticals, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Drais Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Drais Pharmaceuticals founded?

    Drais Pharmaceuticals was founded in 2007.

  • Where is Drais Pharmaceuticals's headquarters?

    Drais Pharmaceuticals's headquarters is located at 520 US Highway 22, Bridgewater.

  • What is Drais Pharmaceuticals's latest funding round?

    Drais Pharmaceuticals's latest funding round is Series A.

  • How much did Drais Pharmaceuticals raise?

    Drais Pharmaceuticals raised a total of $15M.

  • Who are the investors of Drais Pharmaceuticals?

    Investors of Drais Pharmaceuticals include InterWest Partners and Sutter Hill Ventures.

  • Who are Drais Pharmaceuticals's competitors?

    Competitors of Drais Pharmaceuticals include Horizon Therapeutics, Zosano Pharma, Cornerstone Pharmaceuticals, Aegerion Pharmaceuticals, Hyperion Therapeutics and 9 more.

Compare Drais Pharmaceuticals to Competitors

I
IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

V
Verva Pharmaceuticals

Verva Pharmaceuticals is an exciting, clinical-stage pharmaceutical company focused on the discovery and development of therapies to treat metabolic diseases (formerly Adipogen).

C
Cobrek Pharmaceuticals

Cobrek Pharmaceuticals is engaged in the research, development and commercialization of prescription drug therapies, delivery systems and applications that improve quality of life and enhance the lifestyle of patients across the adolescent and adult age-spectrum with particular attention to the needs of the aging population.

Radius Logo
Radius

Radius Health is a biopharmaceutical company focused on developing new therapeutics to treat osteoporosis and other women's health conditions. It is committed to the development of therapeutics for the osteoporosis market. The company's lead product candidate, BA058-SC, is in effect to reduce the risk of complications associated with osteoporosis, such as fractures and has a transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. The company was founded in 2003 and is based in Boston, Massachusetts.

O
Osteologix

Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.

M
Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.